Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/40673
Title: | A retrospective, multicenter study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real-world setting in Belgium | Authors: | Nasreddine, Rakan Florence, Eric Yombi, Jean Cyr Henrard, Sophie Darcis, Gilles Van Praet, Jens Vandekerckhove, Linos Allard, Sabine Demeester, Rémy MESSIAEN, Peter Ausselet, Nathalie Delforge, Marc De Wit, Stéphane |
Corporate Authors: | Belgian Research on AIDS and HIV Consortium (BREACH) | Issue Date: | 2022 | Source: | HIV Glasgow, Glasgow, 23 – 26 October 2022 | Abstract: | Conclusion • Several RCTs have demonstrated BIC/FTC/TAF to be a first-line option for treatment-naïve and experienced PLWH [1-4]. • Real-world studies provide complementary information to RCTs and ensure that those results can be generalized to broader populations seen in daily practice. • The aim of this study was to describe the Belgian HIV population treated with BIC/FTC/TAF and to evaluate its efficacy, durability, and tolerability in a real-world setting. | Document URI: | http://hdl.handle.net/1942/40673 | Category: | C2 | Type: | Conference Material |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
poster 9 PowerPoint Presentation.pdf | Conference material | 943.06 kB | Adobe PDF | View/Open |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.